Influence of atopy on the clinical manifestations of coronavirus infection in adult volunteers

KATHLEEN A. CALLOW, D. A. J. TYRRELL, R. J. SHAW*, PENNY FITZHARRIS*, A. J. WARDLAW* and A. B. KAY*

MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire and *Cardiothoracic Institute, Brompton Hospital, London, U.K.

(Received in original form 22 April 1987 and in revised form 19 August 1987; accepted for publication 8 September 1987)

Summary
In an attempt to understand the relationship between viral upper respiratory tract infection and the underlying virological and immunological mechanisms, thirty-four volunteers were inoculated intranasally with coronavirus 229E; subsequent virus shedding and/or antibody rises, indicating active infection, were observed in twenty-nine. There was a greater increase in independently measured scores of clinical severity, e.g. cold symptoms, in those with detectable IgE in nasal secretions ($P < 0.01$). A similar association was found between clinical scores and serum IgE concentrations $\geq 150$ IU/ml, but the relationship with systemic atopy, as assessed by skin-prick tests to common allergens, was less marked. A more detailed study of twelve of the infected volunteers failed to explain these findings on the basis of mast cell mediator release, as concentrations of leukotriene B$_4$, the sulphidopeptide leukotriene C$_4$, and histamine, were not appreciably elevated in the nasal secretions following virus inoculation. Similarly, there was no evidence that circulating coronavirus specific IgE was produced. Thus, this study suggests that atopy may be related to the severity of cold symptoms produced by coronavirus 229E, although the exact connection has yet to be determined.

Introduction
In allergic subjects, particularly asthmatics, exacerbations commonly occur during respiratory virus infections suggesting the possible involvement of IgE [1]. There is little experimental evidence to confirm the relationship between symptoms of viral infection and atopy, despite the ready availability of measures of atopy, such as
reactions to skin-prick testing and circulating IgE concentration [2–5]. Local IgE in secretions may also be important, as it is also associated with atopy [6, 7] and may be elevated even when serum concentrations are normal [8].

In this study all these measures of atopy have been made in volunteers infected with coronavirus 229E and compared with the severity of the cold, assessed subjectively and objectively by an independent medical observer.

In order to elucidate any direct role of mast cells or other mediator releasing cells, measurement was made of recognized mediators of nasal allergy in twelve of these infected volunteers. Both the sulphidopeptide leukotriene C4 (LTC4) and leukotriene B4 (LTB4), as well as histamine, have been shown to be released into nasal secretions after nasal allergen challenge [9,10]. Histamine also appears to be released into nasopharyngeal secretions during parainfluenza and respiratory syncytial virus (RSV) infections [11, 12]. In parainfluenza, RSV and rubella infections, specific serum and nasal IgE concentrations have been shown to be raised [11–13] and it has been suggested that it contributes to the wheezing in respiratory infections [11, 12].

Finally, evidence of increased infiltration of the nasal mucosa by leucocytes during infection was also sought.

Subjects and methods

Volunteers
Normal adult volunteers, between the ages of 18 years and 50 years, were recruited by a procedure that excludes those with recognized allergic disease, e.g. allergic rhinitis. Isolation, inoculation and assessment procedures have been described elsewhere [14, 15]. Thirty-four volunteers, twenty-five females and nine males, were inoculated intranasally with coronavirus 229E, contained in a filtered nasal wash, as previously described [16]. The trial was approved by the Northwick Park Ethical Committee.

Clinical scores
A daily clinical score was calculated from the record of nasal blockage, rhinorrhoea, sneezing and systemic symptoms. The numbers of used tissues and pyrexia are given heavy weighting [17]. The clinical score of all volunteers before virus challenge was zero.

Nasal washings
These were performed daily on 3 consecutive days before, and for 6 days after, virus inoculation. After volunteers refrained from nasal blowing for 1 hr, 1-ml portions of normal saline were instilled into each nostril with the head tilted backwards 30°. The individual expelled the mixture of mucus and saline into a plastic beaker [10]. This was repeated until 8 ml of wash fluid were recovered, followed by vortex mixing with glass beads to disperse the mucus. Aliquots for immunoglobulin measurement were centrifuged to sediment the mucus, and supernatants were stored at −20°C. Other aliquots for histamine and leukotriene assay, and virus culture were stored at −70°C. The presence of virus was detected using the C-16 line of MRC-C cells [18].

Enzyme-linked immunosorbent assay (ELISA) for total IgE in nasal washings
Washing methods, substrate and optical density (OD) measurements have been described elsewhere [16]. Nunc round-bottomed immunoplates (Gibco Ltd, Uxbridge,
U.K.) were coated with rabbit anti-human IgE antiserum (Hoechst UK Ltd, Hounslow, U.K.) at 1:3000 overnight at 4°C. After washing, plates were incubated with 0.1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) for 2 hr at room temperature (RT). Nasal washings were added, undiluted, and incubated for 6 hr at 4°C. Goat anti-human IgE conjugated to alkaline phosphatase (Sigma Chemical Co., Ltd, Poole, U.K.) at 1:1000 was then added and left overnight at 4°C. After addition of the substrate, plates were read at 2 hr with a Titertek Multiskan ELISA reader (Flow Laboratories Ltd, Irvine, U.K.). Washings were considered positive for IgE if the OD was > OD + 2 standard deviations (s.d.) of that of the controls without nasal washing. This represented a minimum detectable limit of about 0.2 IU/ml.

**ELISA for total circulating IgE**

IgE in sera collected prior to, 6 days (intermediate), and 21 days (convalescent) after virus challenge, was measured as described above, omitting the blocking step with BSA. A standard curve on each plate used a standard human serum IgE (provided by Dr E.B. Mitchell, formerly of the Clinical Research Centre, Harrow, U.K.), and serum samples were diluted at 1 and 10 in 0.1% BSA and incubated for 4 hr at RT. The OD of the dilution that fell on the linear part of the standard curve was used to calculate the concentration. Concentrations of IgE >150 IU/ml were considered to be abnormally high [4,19,20].

**Extraction of leukotrienes from nasal washings**

Nasal wash fluid was mixed with an equal volume of HPLC grade methanol (Rathburn, Walkerburn, U.K.) using a Silverson grinder (Silverson Ltd, Chesham, U.K.) and stored at -20°C. After acidification to pH 4.0 with acetic acid the precipitate was removed by centrifugation (12,000 × g, 10 min, 4°C) and the supernatant was diluted to give a 10% methanol/H2O solution. The leukotrienes were then extracted using C18 Sep-paks (Water Associates, Northwick, U.K.) [10] and resuspended in PBS buffer.

**Leukotriene measurement**

The measurement of LTC4 and LTB4 by a double antibody radioimmunoassay (using antisera supplied by Dr E. Hayes, Merck Sharp & Dohme, Rahway, NJ, U.S.A.) has been described in detail elsewhere [21-23].

Briefly, rabbit anti-LTC4 or anti-LTB4 were incubated with unknown or dilutions of synthetic LTC4 or LTB4 (a gift from Dr J. Rockach, Merck Forest Laboratories, Quebec, Canada) together with 14,15-3H-LTC4 or 14,15-3H-LTB4 (New England Nuclear (NEN), Southampton, U.K.) together with normal rabbit immunoglobulins in PBS containing p-methyl sulphonyl fluoride (1 × 10^-4 M) and 0.25% gelatin. After 2-hr incubation at 4°C, goat anti-rabbit immunoglobulin (Biorad, Watford, U.K.) diluted in 5% polyethylene glycol (PEG) 6000 was added. Two hours later the tubes were centrifuged (15,000 × g, 15 min, 4°C). The radioactivity in the supernatant was measured with an LKB beta-1217 counter using Aquasol II (NEN) as scintillant. All assays were performed in duplicate and the leukotriene concentration determined using a smoothed spline computed analysis. Recovery experiments using synthetic leukotrienes confirmed a recovery of 82±9% for LTC4 and 100% for LTB4. The baseline pre-challenge nasal washing leukotriene concentration was obtained from the mean of 3 consecutive days prior to virus inoculation.
Recovery and measurement of histamine from nasal washings
After collection of the nasal washing, an aliquot of 200 µl wash fluid was mixed with 20 µl of 0.1 M EDTA pH 7.4 and stored at -80°C. Histamine measurement used a specific isotope enzymatic assay modified from that of Guilloux et al. [24], which had a sensitivity of 0.5 ng/ml. In brief, the sample was incubated with methyl transferase obtained from rat kidney in the presence of the tritium-labelled methyl donor S-adenylmethionine. The labelled methyl histamine so formed was extracted in chloroform and the activity of the sample compared with a standard curve obtained using histamine dihydrochloride (Sigma Ltd). On one set of samples a fluorimetric assay for histamine was performed and the results agreed closely with those obtained using the above methods.

Specific IgE in sera
Indirect ELISA. Plates were coated with coronavirus 229E or control antigen as described elsewhere [16]. Sera diluted 1/10 in BSA diluent were incubated for 5 hr at RT, and IgE was detected as described for total IgE. The peroxidase-conjugated goat anti-human IgE (Miles Laboratories Ltd, U.K.), used by Welliver et al. [11, 12, 25], was not used as it was found to have a low-level cross-reactivity with IgG.

IgE capture ELISA. Plates were coated with anti-human IgE produced in goats (Hoechst) overnight as described for measurement of total IgE. Sera were diluted 1/10 or 1/30 in BSA diluent and incubated for 3 hr at RT. Virus or control antigen at 5% was added and left for 3 hr at RT. Rabbit antiserum to coronavirus 229E diluted 1:1000 was added and left overnight at 4°C, followed by alkaline phosphatase conjugated to anti-rabbit IgG (Miles Laboratories) at 1:4000 for 4 hr at RT. Substrate was added and ODs read at 405 nm as described.

Using both methods for measuring specific IgE, optimal dilutions of reagents were determined by chequerboard titrations. Optical densities obtained with control antigens were subtracted from those obtained with virus. Sera were considered positive if these adjusted ODs were >OD + 2 s.d. of the controls without serum.

Allergen skin tests
Skin-prick tests were performed using standard allergens to grass pollen, trees, shrubs, Dermatophagoides sp., house dust, cat, dog, negative and positive histamine control (Pharmacia, Uppsala, Sweden). None of the volunteers developed a weal ≥3 mm to the negative control.

Nasal cytology
Nasal cytology smears were collected before and 3 and 6 days after virus challenge, by gently scoring the interior turbinate of each nostril with a specially designed nasal probe. The material was smeared onto a glass microscope slide, allowed to air-dry, fixed in methanol and stained with May-Grunwald/Giemsa. The slides were coded and counted blind by two independent investigators. A differential count was performed counting 200 cells.

Statistical methods
The statistical analyses were performed on a Sirius I microcomputer using the program, Statistical Package for Personal Computers (SPP, Patrick Royston, Clinical
Table I. Pre-inoculation measures of atopy of volunteers subsequently infected with coronavirus and their clinical scores

| Subject | No. positive skin tests with common allergens* | Nasal washing IgE† | Total serum IgE (IU/ml) | Total clinical score |
|---------|-----------------------------------------------|---------------------|-------------------------|---------------------|
| M.D.   | 0                                             | +                   | 50                      | 71.5                |
| B.W.   | 4                                             | +                   | 850                     | 51.5                |
| E.M.   | 0                                             | +                   | 60                      | 29                  |
| P.W.   | 1                                             | +                   | 340                     | 31.5                |
| M.B.   | 0                                             | +                   | 425                     | 30.5                |
| B.W.   | 0                                             | -                   | 157                     | 29                  |
| L.M.   | 0                                             | +                   | 50                      | 24.5                |
| S.H.   | 3                                             | +                   | 74                      | 24                  |
| B.B.   | 2                                             | +                   | 37                      | 23                  |
| K.S.   | 0                                             | +                   | 12                      | 23                  |
| V.D.   | 0                                             | +                   | 22                      | 22.5                |
| S.C.   | 1                                             | +                   | 5                       | 22.5                |
| M.G.   | 0                                             | +                   | 69                      | 20                  |
| M.T.   | 0                                             | -                   | 15                      | 20                  |
| A.B.   | 0                                             | +                   | 78                      | 19                  |
| T.S.   | 0                                             | +                   | 43                      | 19                  |
| S.R.   | 4                                             | -                   | 25                      | 17.5                |
| H.G.   | 1                                             | -                   | 13                      | 17.5                |
| R.B.   | 0                                             | +                   | 1050                    | 12                  |
| H.G.   | 0                                             | -                   | 5                       | 9.5                 |
| R.D.   | 0                                             | -                   | 5                       | 8.5                 |
| S.W.   | 0                                             | +                   | 1                       | 2                   |
| R.D.   | 3                                             | -                   | 145                     | 0.5                 |
| S.M.   | 5                                             | +                   | 225                     | 0                   |
| L.C.   | 0                                             | -                   | 108                     | 0                   |
| K.G.   | 0                                             | -                   | 75                      | 0                   |
| P.C.   | 0                                             | -                   | 59                      | 0                   |
| J.H.   | 0                                             | -                   | 15                      | 0                   |
| H.S.   | 0                                             | -                   | 13                      | 0                   |

* A positive skin test indicates a ≥3 mm weal.
† (+) Indicates ELISA ODs ≥ control OD + 2 s.d. on 1 or more days before virus inoculation.

Results

Infection, illness and atopic status of volunteers

Of thirty-four volunteers inoculated with coronavirus 229E, twenty-nine became infected as indicated by virus shedding and twenty-three had some respiratory symptoms, with clinical scores ranging from 0.5 to 71.5 (Table I). Nine of the infected volunteers had a positive skin test to one or more allergens and six, not necessarily the
same individuals, had high (≥150 IU/ml) serum IgE concentrations before the trial (Table 1). Seventeen volunteers had detectable amounts of nasal IgE and only eight were negative for all three measures of atopy.

**Agreement between the measures of atopy**

Those volunteers who had detectable nasal IgE had almost four times as much serum IgE compared with those who had no detectable IgE (Fig. 1). However, eleven volunteers who had negative skin tests had detectable nasal IgE and three had high concentrations of IgE in their sera (Table 1). None of these relationships was significant at \( P<0.05 \).

**Relationship of measures of atopy to clinical scores**

The presence or amount of local and serum IgE and the result of skin tests were all related to clinical scores (Fig. 2). The mean clinical score of those with detectable amounts of nasal IgE was over three times higher than the mean score of those with undetectable IgE (\( P<0.01 \)). The mean clinical score of those with higher than normal serum IgE was about one and a half times higher than that of those volunteers whose serum IgE was within the normal range, although the difference was not statistically significant (in a two-tailed test). The mean clinical score of volunteers with positive skin tests was slightly higher than those with a negative test, although again this did not reach statistical significance. Groups that were positive for all three measures of atopy, or at least two of them, had a considerably higher mean score than the rest, although the differences were not statistically significant. The group that was positive for at least one of the criteria had a mean score of 23.8 compared with 4.7 for those who were negative for all three (\( P=0.001 \)). None of the indicators of atopy appeared to be
related to the amount of duration of virus shedding or to the size of specific IgG antibody rises (data not shown).

The following studies were carried out in twelve of the infected volunteers to try to elucidate the role of possible mediators.

**Leukotrienes and histamine in nasal washings and relationship with measures of atopy and clinical scores**

The concentration of the leukotrienes LTB$_4$ and LTC$_4$ in nasal washings was very low throughout the trial, compared with concentrations observed following provocation [10] (Fig. 3a). The mean concentrations showed fluctuations on different days, which did not appear to correlate with the changes in mean clinical scores (Fig. 3b). However, on most days after infection, LTC$_4$ concentrations in individual volunteers correlated positively with the clinical score, while with LTB$_4$ the reverse was the case; these correlations were not statistically significant however (data not shown).

Those volunteers classified as atopic by detectable IgE levels in nasal washing tended to have more LTC$_4$ ($P = 0.028$) and less LTB$_4$ (not significant) in their pre-inoculation washings than the non-atopics (Table 2). These differences persisted throughout the trial but values were so low that they may not be biologically important.

Histamine concentrations were also very low or undetectable. Only four volunteers had detectable amounts in their pre-trial washings; all four also had detectable nasal IgE and higher than average LTC$_4$ concentrations (Table 2). There was no indication that histamine concentrations increased after infection (data not shown) while one volunteer with high serum IgE (B.W.) and three with nasal IgE had no detectable histamine at any stage.

**Coronavirus-specific IgE in serum**

Optical densities significantly higher than the control were detected in only two pre-challenge sera (M.B. and L.M.) using the indirect ELISA. Because of these largely
Fig. 3. (a) Mean LTC4 (○) and LTB4 (●) concentrations in volunteer nasal washings collected prior to (PRE: mean of 3 successive days before inoculation), and daily after intranasal virus inoculation (mean ± s.e.m., n = 12). (b) Mean clinical score of volunteer's cold symptoms prior to (PRE), and daily after intranasal virus inoculation (mean ± s.e.m., n = 12). Dotted lines indicates mean change in six volunteers only.

Table 2. Clinical scores and pre-inoculation measures of mediators of allergy in volunteers infected with coronavirus

| Subject  | Clinical score | Total IgE* | LTC4 (ng/ml) | LTB4 (ng/ml) | Histamine† |
|----------|----------------|------------|--------------|--------------|------------|
| B.W.     | 51-5           | +          | 0-102        | 0-075        | -          |
| E.M.     | 39             | +          | 0-144        | 0-090        | +          |
| P.W.     | 31-5           | +          | 0-146        | 0-106        | +          |
| M.B.     | 30-5           | +          | 0-158        | 0-079        | +          |
| L.M.     | 24-5           | +          | 0-142        | 0-173        | -          |
| S.C.     | 22-5           | +          | 0-138        | 0-281        | -          |
| M.T.     | 20             | -          | 0-141        | 0-280        | -          |
| R.B.     | 12             | +          | 0-167        | 0-115        | +          |
| H.G.     | 9-5            | -          | 0-134        | 0-078        | -          |
| R.D.     | 8-5            | -          | 0-062        | 0-124        | -          |
| K.G.     | 0              | -          | 0-137        | 0-262        | -          |
| J.H.     | 0              | -          | 0-065        | 0-063        | -          |

* (+) Indicates ELISA ODs ≥ control OD + 2 s.d. on 1 or more days before challenge.
† (+) Indicates ≥1 ng/ml on 1 or more days before challenge.
negative results an IgE capture ELISA was then tried. With this method, none of the pre-challenge sera appeared to contain specific IgE, although the convalescent sera of two volunteers (L.M. and S.C.) appeared to contain trace amounts, as did one intermediate serum (K.G.). No other samples from any volunteer contained detectable specific IgE. There was also no evidence that total IgE concentrations in the sera increased after infection (data not shown).

**Nasal cytology**

Most of the cells in the scrapes were epithelial or goblet cells. Neutrophils were occasionally seen but there were no differences between the pre- and post-infective cytology, except in one volunteer (H.G.) where neutrophils were present after infection, and another (S.C.) where neutrophils were seen before infection but not after. No eosinophils were seen in any subject.

**Discussion**

The variation in the indices of atopy used in this study is well recognized [20, 26, 27] although, as in other studies, the best agreement was between serum and nasal IgE concentrations [28, 29]. Detectable nasal IgE concentrations were most closely associated with a more severe cold, as assessed by a combination of subjective and objective clinical scores ($P<0.01$), followed by elevated serum IgE and positive skin-test results.

This interrelationship between the clinical severity of rhinitis and the presence of allergic processes is in accordance with the known capacity of virus infection to trigger asthma attacks in susceptible individuals [1, 30, 31].

Rhinovirus infections have been associated with asthma and bronchitis in both children and adults [1, 30, 31], but exacerbations only occurred in a minority of asthmatic adults during experimental rhinovirus infection [32]. No consistent association between the severity of colds and circulating or local IgE concentrations has yet been found in volunteers infected with rhinovirus (Callow, unpublished observation).

A number of possible mechanisms underlying the relationship were explored in this study. There was no evidence of coronavirus-specific circulating IgE prior to, or following, viral inoculation, and it may be that atopic individuals do not become sensitized to viral antigens [33]. In this case, direct triggering of cells, such as nasal mast cells or basophils, via specific surface-bound IgE directed against the virus would be unlikely.

The lack of involvement of mast cells or basophils was further suggested by the failure of this study to identify any rise in the concentration of histamine, sulphidopeptide leukotriene C$_4$ or leukotriene B$_4$ following virus inoculation. The small but statistically significant differences in baseline leukotriene concentrations in atopic and non-atopic volunteers were thought to be too small to be biologically important.

Similarly, the cytological findings did not identify any influx of inflammatory cells, in particular eosinophils, characteristic of the allergic response.

Although a significant increase of total protein is found in nasal secretions, following virus infection [34, 35; Callow, unpublished observations], other studies have, like ours, failed to detect a similar increase in histamine or leukotriene concentrations [36]. The observed increase in concentrations of these mediators
following allergen provocation may be due to the fact that inflammation and release of mediators is due to a large amount of allergen given in one dose whereas in virus infections, such effects are due to small amounts of infectious virus that are released over a much longer period. Furthermore, studies with allergen provocation are usually done with overtly atopic subjects [10], whereas the atopy detected in our volunteers was mild and not accompanied by allergic symptoms.

This study has raised the possibility of a relationship between the symptoms of a cold and the presence of atopy, in particular as detected by intranasal IgE concentrations. Studies attempting to dissect the mechanism of this relationship failed to identify a common pathway for viral and allergic rhinitis. Possibly an immunological imbalance, either humoral or cell-mediated, which has been shown to be associated with atopy [33, 37, 38] may independently lead to both atopy and increased severity of symptoms of virus infection.

Nevertheless, the results of this study show that increasing our understanding of any common pathways between virus- and allergen-induced rhinitis may provide insights which would have therapeutic implications for both conditions.

Acknowledgment
We thank the staff and volunteers of the MRC Common Cold Unit for their assistance in this study.

References
1. Gregg I. Provocation of airflow limitation by viral infection: implication for treatment. Eur J Respir Dis 1983; 64 (suppl 128):369-79.
2. Berg T, Johansson SGO. IgE concentrations in children with atopic diseases. Int Arch Allergy Appl Immunol 1969; 36:219-32.
3. Johansson SGO, Bennich H, Berg T, Hogman C. Some factors influencing the serum IgE levels in atopic diseases. Clin Exp Immunol 1970; 6:43-7.
4. Wittig HJ, Belloit J, de Filippis I, Royal G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 1980; 66:305-13.
5. Barbee RA, Halonen M, Lebowitz M, Burrows B. Distribution of IgE in a community population sample: correlations with age, sex and allergen skin test reactivity. J Allergy Clin Immunol 1981; 68:106-11.
6. Johansson SGO, Deuschl H. Immunoglobulins in nasal secretion with special reference to IgE. Int Arch Allergy Appl Immunol 1976; 52:364-75.
7. Illum P, Balle V. Immunoglobulins in nasal secretions and nasal mucosa in perennial rhinitis. Acta Otolaryngol 1978; 86:135-41.
8. Merrett TG, Houri M, Mayer ALR, Merrett J. Measurement of specific IgE antibodies in nasal secretion—evidence for local production. Clin Allergy 1976; 6:69-73.
9. Creticos PS, Peters SP, Adkinson NF et al. Peptide leukotriene release after antigen challenge to patients sensitive to ragweed. N Engl J Med 1984; 310:1626-30.
10. Shaw RJ, Fitzharris P, Cromwell O, Wardlaw AJ, Kay AB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy 1985; 40:1-6.
11. Welliver RC, Wong DT, Sun M, Middleton E Jr, Vaughan RS, Ogra PL. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med 1981; 305:841-6.
12. Welliver RC, Wong DT, Middleton E Jr, Sun M, McCarthy N, Ogra PL. Role of parainfluenza virus-specific IgE in pathogenesis of croup and wheezing subsequent to infection. J Pediatr 1982; 101:6; 889-96.
13. Salonen E-M, Hovi T, Meurman O, Vesikari T, Vaheri A. Kinetics of specific IgA, IgD, IgE, IgG and IgM antibody responses in rubella. J Med Virol 1985; 16:1-9.
14. Beare AS, Reed SE. The study of antiviral compounds in volunteers. In: Oxford JS, ed. Chemoprophylaxis and Virus Infections of the Respiratory Tract. Vol II. Cleveland: CRC Press, 1977:27-55.
Atopy on clinical manifestations of coronavirus infection

15 Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DAJ. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24:713–5.

16 Callow KA. Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. J Hyg Camb 1985; 95:173-89.

17 Tyrrell DAJ. Common Cold and Related Diseases. London: Edward Arnold Ltd, 1965:51–2.

18 Phillpotts RJ. Clones of MRC-C cells may be superior to the parent line for the culture of 229E-like strains of human respiratory coronavirus. J Virol Methods 1983; 6:267–9.

19 Zetterstrom O, Johansson SGO. IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy. Allergy 1981; 36:537–47.

20 Geha RS. Continuing medical education: human IgE. J Allergy Clin Immunol 1984; 74:109–22.

21 Cromwell O, Shaw RJ, Walsh GM, Mallet AI, Kay AB. Inhibition of leukotriene C4 and B4 generation by human eosinophils and neutrophils with the lipoxygenase pathway inhibitors U-60,257 and BW755C. Int J Immunopharmacol 1985; 7:775–81.

22 Hayes EC, Lombardo DL, Girard Y et al. Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radio-immunoassay. J Immunol 1983; 131:429–33.

23 Shaw RJ, Cromwell O, Kay AB. Preferential generation of leukotriene C4 by human eosinophils. Clin Exp Immunol 1984; 56:716–22.

24 Guilloux L, Hartmann D, Ville G. Enzymatic isotopic assay for human plasma histamine. Clin Chim Acta 1981; 116:269–75.

25 Welliver RC, Sun M, Rinaldo D, Ogra PL. Respiratory syncytial virus-specific IgE responses following infection: evidence for a predominantly mucosal response. Pediatr Res 1985; 19:420–4.

26 Houri M, Mayer ALR, Houghton LE, Jacobs D. Correlation of skin, nasal and inhalation tests with the IgE in the serum, nasal fluid and sputum. Clin Allergy 1972; 2:285–98.

27 Buckley CE, Larrick JW, Kaplan JE. Population differences in cutaneous methacholine reactivity and circulating IgE concentrations. J Allergy Clin Immunol 1985; 76:847–54.

28 Ishizaka K, Newcomb RW. Presence of γE in nasal washings and sputum from asthmatic patients. J Allergy 1970; 46:197–204.

29 Braun JJ, Pauli G, Bessot JC, Thierry R, Conraux C. Local and serum IgE in vasomotor rhinitis. Rhinology 1982; 20:3–12.

30 Minor TE, Dick EC, Demeo AN, Ouellette JJ, Cohen M, Reed CE. Viruses as precipitants of asthmatic attacks in children. J Am Med Assoc 1974; 227:292–8.

31 Minor TE, Dick EC, Baker JW, Ouellette JJ, Cohen M, Read CE. Rhinovirus and influenza type A infections as precipitants of asthma. Am Rev Respir Dis 1976; 113:149–53.

32 Halperin SA, Eggleston PA, Beasley P et al. Exacerbations of asthma in adults during experimental rhinovirus infection. Am Rev Respir Dis 1985; 132:976–80.

33 Katz DH. Regulation of the IgE system: experimental and clinical aspects. Allergy 1984; 39:81–106.

34 Rossen RD, Butler WT, Cate TR, Szwed CF, Couch RB. Protein composition of nasal secretion during respiratory virus infection. Proc Soc Exp Biol (NY) 1965; 119:1169–76.

35 Butler WT, Waldmann TA, Rossen RD, Gordon Douglas R Jr, Couch RB. Changes in IgA and IgG concentrations in nasal secretions prior to the appearance of antibody during viral respiratory infection in man. J Immunol 1970; 105:584–91.

36 Naclerio RM, Proud D, Peters SP et al. Inflammatory mediators in nasal secretions during induced rhinitis. Clin Allergy 1986; 16:101–10.

37 Leung DYM, Geha RS. Regulation of IgE synthesis in man. Clin Immunol Rev 1984; 3:1–24.

38 Haeney M. An introduction to allergic disease. London. J Roy Coll Physicians 1985; 19:147–53.
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.